olivLaw · US equity research
Scinai Immunotherapeutics Ltd. SCNI
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
Scinai Immunotherapeutics is an Israeli biopharmaceutical company combining inflammation and immunology drug development with a CDMO business offering contract development and manufacturing for small biotech companies. The company operates under a going concern qualification, with cash of $1.6 million at year-end 2025.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 05 Nov 2026, Scinai Immunotherapeutics Ltd. (SCNI) stock was 0.45 USD (+0.45% on the day), with market capitalisation 6.3 bn USD, P/E 112.8 on diluted EPS of 0.00 USD over the last 12 months, beta 0.75, 52-week range 0.45–12.40 USD. Latest reported quarter (Q1 2023): net income of -3.5 m USD, diluted EPS -0.00 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 22.6
- oversold (≤ 30)
- Bollinger (20, 2)
- 0.19 – 1.18
- in the lower half of the band · %B 0.26 · band width 144.0%
- SMA 50 / 200
- 1.32 / 4.29
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.26 / -0.29
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −63.0% | −5.9% | −57.1 pp | — |
| 3 months | −82.6% | −4.6% | −78.0 pp | — |
| 6 months | −91.7% | +0.2% | −91.9 pp | — |
| Year to date | −93.7% | +7.4% | −101.1 pp | — |
| 1 year | −96.1% | +8.2% | −104.3 pp | +3.3% |
| 3 years | −99.3% | +68.4% | −167.8 pp | +5.3% |
| 5 years | −100.0% | +56.5% | −156.5 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q1 2023 · 31 Mar 2023
Quarterly statements · USD
| Fiscal year | Q1 '22 | Q1 '23 |
|---|---|---|
| Research & development | 1.2 m | 2.0 m |
| Operating income | -2.6 m | -3.2 m |
| Depreciation & amortisation | 134.0 k | 138.0 k |
| Net income | -2.5 m | -3.5 m |
| Diluted EPS | -0.00 | -0.00 |
| Operating cash flow | -1.1 m | -3.1 m |
| Capex | 521.0 k | 6.0 k |
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 0 percentile of its own 2-quarter history (min 14,875.0, median 22,237.5, max 29,600.0; quarters with earnings only).
Fiscal years
| Fiscal year | 2017 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable | unavailable | unavailable | 658.0 k | 1.3 m |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | +99.2% |
| Net income | -10.0 m | -1.4 m | -8.2 m | -5.8 m | -6.5 m | 4.8 m | -8.3 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | −273.2% |
| Diluted EPS | unavailable | unavailable | -0.02 | 0.01 | 0.00 | unavailable | unavailable |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | −60.0% | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | unavailable | unavailable | 728.9% | -633.6% |
| Free cash flow | -4.2 m | -24.5 m | -7.6 m | -8.1 m | -10.0 m | -6.3 m | -6.1 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 1.7 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 8.1 m USD
- Total assets
- 11.6 m USD
- Debt / equity
- unavailable
- Current ratio
- 1.30x
- ROE
- -91.9%
- ROA
- -66.3%
- FCF margin
- -461.9%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | 658.0 k | 1.3 m | SEC (XBRL)· 01 Apr 2026verified |
| Cost of revenue | — | — | — | — | 1.2 m | 4.0 m | SEC (XBRL)· 01 Apr 2026verified |
| Gross profit | — | — | — | — | -580.0 k | -2.7 m | SEC (XBRL)· 01 Apr 2026verified |
| Research & development | 16.0 m | 3.2 m | 5.8 m | 5.2 m | 5.5 m | 2.4 m | SEC (XBRL)· 01 Apr 2026verified |
| SG&A | — | 7.6 m | 5.3 m | 4.5 m | 2.5 m | 2.5 m | SEC (XBRL)· 01 Apr 2026verified |
| Operating income | — | -10.9 m | -11.1 m | -9.7 m | -8.6 m | -7.5 m | SEC (XBRL)· 01 Apr 2026verified |
| Depreciation & amortisation | — | 471.0 k | 562.0 k | 514.0 k | 1.6 m | 1.4 m | SEC (XBRL)· 01 Apr 2026verified |
| EBITDA | — | -10.4 m ≈ | -10.5 m ≈ | -9.2 m ≈ | -7.0 m ≈ | -6.1 m ≈ | SEC (XBRL)· 01 Apr 2026derived |
| Interest expense | 4.9 m | 336.0 k | 351.0 k | 343.0 k | — | — | SEC (XBRL)· 15 May 2024verified |
| Net income | -1.4 m | -8.2 m | -5.8 m | -6.5 m | 4.8 m | -8.3 m | SEC (XBRL)· 01 Apr 2026verified |
| Diluted EPS | — | -0.02 | 0.01 | 0.00 | — | — | SEC (XBRL)· 07 May 2025verified |
| Weighted average diluted shares | — | 564.6 m | 754.1 m | 1.6 bn | 3.2 bn | 9.3 bn | SEC (XBRL)· 01 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 3.1 m | 17.4 m | 14.1 m | 4.9 m | 2.0 m | 1.7 m | SEC (XBRL)· 01 Apr 2026verified |
| Receivables | 375.0 k | 325.0 k | — | — | 83.0 k | 73.0 k | SEC (XBRL)· 01 Apr 2026verified |
| Current assets | 3.3 m | 17.8 m | 14.4 m | 5.4 m | 2.4 m | 2.1 m | SEC (XBRL)· 01 Apr 2026verified |
| Property, plant & equipment, net | 12.3 m | 12.4 m | 11.2 m | 10.8 m | 9.2 m | 7.8 m | SEC (XBRL)· 01 Apr 2026verified |
| Total assets | 17.7 m | 32.0 m | 27.1 m | 17.5 m | 13.4 m | 11.6 m | SEC (XBRL)· 01 Apr 2026verified |
| Accounts payable | 581.0 k | 999.0 k | — | — | — | — | SEC (XBRL)· 28 Mar 2022verified |
| Short-term debt | — | 375.0 k | 382.0 k | — | — | — | SEC (XBRL)· 17 Apr 2023verified |
| Current liabilities | 20.0 m | 2.4 m | 2.3 m | 1.8 m | 1.8 m | 1.6 m | SEC (XBRL)· 01 Apr 2026verified |
| Equity | -4.5 m | 982.0 k | -1.8 m | -4.6 m † | 10.0 m † | 8.1 m † | SEC (XBRL)· 01 Apr 2026verified |
| Shares outstanding at year end | 461.3 m | 573.3 m | — | 1.9 bn | 3.4 bn | 13.9 bn | SEC (XBRL)· 01 Apr 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -22.6 m | -7.4 m | -7.3 m | -9.4 m | -6.3 m | -6.0 m | SEC (XBRL)· 01 Apr 2026verified |
| Capex | 1.9 m | 139.0 k | 836.0 k | 637.0 k | 12.0 k | 24.0 k | SEC (XBRL)· 01 Apr 2026verified |
| Free cash flow | -24.5 m ≈ | -7.6 m ≈ | -8.1 m ≈ | -10.0 m ≈ | -6.3 m ≈ | -6.1 m ≈ | SEC (XBRL)· 01 Apr 2026derived |
| Investing cash flow | -1.8 m | -139.0 k | -836.0 k | -637.0 k | -12.0 k | -24.0 k | SEC (XBRL)· 01 Apr 2026verified |
| Financing cash flow | 4.3 m | 21.4 m | 6.8 m | 1.1 m | 3.4 m | 5.8 m | SEC (XBRL)· 01 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 18.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 6.3 bn USD
Key indicators
Coverage and freshness
Score by group
19% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -633.6% | 33 (vs peers) | 33% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 1.3x | 41 (on a fixed band) | 22% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -0.1% | 0 (on a fixed band) | 44% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial41/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial33/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 1.3 m USD in 2025; YoY growth 99.2%; net margin -633.6%; ROE -91.9%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- FCF yield: -0.1%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 249.0 bn | 26.7 | 78.4% | 24.1% | +10.0% | +33% / +71% |
| GILDGilead Sciences, Inc. | 207.8 bn | — | -22.3% | -12.5% | +2.4% | +33% / +119% |
| MRNAModerna, Inc. | 96.4 bn | — | -39.0% | -141.4% | −39.9% | +829% / +211% |
| RVMDRevolution Medicines, Inc. | 38.4 bn | — | -93.6% | -946.8% | unavailable | +128% / +661% |
| BIIBBiogen Inc. | 36.1 bn | 104.3 | 1.9% | 3.4% | +2.2% | +34% / +4% |
| MESOMesoblast Limited | 18.3 bn | — | -19.0% | -593.9% | +191.4% | −18% / +418% |
| EXELExelixis, Inc. | 16.8 bn | 20.5 | 44.3% | 35.5% | +7.0% | +56% / +215% |
| QGENQiagen N.V. | 11.0 bn | 26.2 | 11.6% | 20.3% | +5.7% | +7% / +20% |
| KYMRKymera Therapeutics, Inc. | 10.9 bn | — | -27.3% | -341.8% | −16.7% | +89% / +517% |
| KRYSKrystal Biotech, Inc. | 8.9 bn | 40.8 | 17.5% | 47.9% | +33.9% | +38% / +188% |
| SCNIScinai Immunotherapeutics Ltd. | 6.3 bn | — | -91.9% | -633.6% | +99.2% | −96% / −99% |
| SRRKScholar Rock Holding Corporation | 5.5 bn | — | -167.8% | — | unavailable | +3% / +261% |
| RLAYRelay Therapeutics, Inc. | 3.8 bn | — | -41.2% | -2,837.0% | +53.4% | +115% / +115% |
| IOVAIovance Biotherapeutics, Inc. | 3.6 bn | — | -29.1% | -58.2% | +60.6% | +213% / +28% |
| DNLIDenali Therapeutics Inc. | 3.2 bn | — | -33.9% | -1,470.5% | unavailable | +1% / +6% |
| VIRVir Biotechnology, Inc. | 1.9 bn | — | -21.8% | -61.0% | −7.6% | +72% / +16% |
| ALVOAlvotech | 1.4 bn | 45.5 | — | 4.8% | +19.7% | −11% / −52% |
| GLUEMonte Rosa Therapeutics, Inc. | 875.9 m | — | -35.3% | -186.2% | +63.5% | −37% / +231% |
| CGEMCullinan Therapeutics, Inc. | 695.0 m | — | -50.3% | — | −100.0% | −5% / +32% |
| ATYRaTYR PHARMA INC | 591.5 m | — | -98.4% | -32,003.7% | −19.1% | +672% / +364% |
| EDITEditas Medicine, Inc. | 391.6 m | — | -118.8% | -157.3% | +25.4% | +6% / −76% |
| CCCCC4 Therapeutics, Inc. | 387.4 m | — | -47.6% | -282.2% | +1.0% | +9% / +81% |
| ALLOAllogene Therapeutics, Inc. | 376.6 m | — | -42.4% | -3,566.7% | −100.0% | −25% / −54% |
| ALECAlector, Inc. | 311.2 m | 6.0 | 47.5% | 23.9% | −79.1% | +57% / −61% |
| LXEOLexeo Therapeutics, Inc. | 238.3 m | — | -46.8% | — | unavailable | −71% / −77% |
1- and 3-year price returns: for SCNI from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 01 Apr 2026; since then the company filed 6-K (20 Oct 2026), 6-K (16 Oct 2026), 6-K (15 Oct 2026), 6-K (13 Oct 2026), 6-K (21 Sept 2026), 6-K (08 Sept 2026).
In brief
Scinai Immunotherapeutics is an Israeli biopharmaceutical company combining inflammation and immunology drug development with a CDMO business offering contract development and manufacturing for small biotech companies. The company operates under a going concern qualification, with cash of $1.6 million at year-end 2025 1.
SWOT
Strengths
- The company combines an R&D and CDMO model, and service revenues give some operational flexibility compared with pure research biotechs 1.
- Laboratory and manufacturing infrastructure in Jerusalem, together with the Yavne site, supports development from early stage to clinical production 1.
- A strategy of non-dilutive funding through grants and loans could reduce reliance on equity capital 1.
Weaknesses
- The company carries a going concern qualification and lacks cash for the next 12 months 1.
- The company is not yet profitable, and CDMO revenues remain limited relative to expenses 1.
- The former lead product M-001 did not meet its clinical endpoints in Phase 3, which forced a full strategic turnaround 1.
Opportunities
- If FENG grant applications are approved, funding could support the IL-17 and PC111 programs 1.
- The Recipharm collaboration could bring clients moving from early development to commercial manufacturing 1.
- The lack of approved therapies for SJS and TEN could make PC111 attractive if clinical data are favorable 1.
Threats
Risks
- Going concernhigh
The going concern qualification and the need for substantial capital could force program cuts or a cessation of operations 1.
- License deadlineshigh
The extensions requested for IND submission might not be granted, and loss of rights would affect the IL-17 program 1.
- PC111 optionmedium
The option lapses if funding is not secured by the August 2026 deadline, and sellers may repurchase shares if no IND is filed by the end of 2028 1.
- Third-party dependencemedium
Programs depend on external licenses and collaborations, and losing these relationships would affect development 1.
- CDMO operational continuitymedium
Operations depend on the Jerusalem and Yavne facilities, and disruptions there would affect revenues 1.
Investment thesis
What would need to be true (bull case)
- If FENG funding is approved, the company could advance PC111 and NanoAb programs without major dilution, and an expanded CDMO could generate more stable revenues 1.
- Integrating Yavne and the Recipharm collaboration could turn CDMO into a recurring revenue source from early-stage clients 1.
- A candidate with clear differentiation in IL-17, or a rare-indication profile for PC111, could attract outside partners 1.
What would break the thesis
What to watch
- FENG decision on the IL-17 and PC111 applicationsJuly 2026
- PC111 option conditions and exercise deadlineAugust 2026
- Outcome of IND extension requests with MPG and UMG2026
- Integration of Scinai Biopharma Services and CDMO revenue trendnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 01 Apr 2026; since then the company filed 6-K (20 Oct 2026), 6-K (16 Oct 2026), 6-K (15 Oct 2026), 6-K (13 Oct 2026), 6-K (21 Sept 2026), 6-K (08 Sept 2026).
The business
Scinai has two complementary units: Scinai R&D, focused on inflammatory and immunological therapies, and Scinai Biopharma Services, which offers CDMO services from Jerusalem and, since February 2026, from the Yavne site acquired from Recipharm Israel 1. The research pipeline is built on NanoAbs, VHH antibody fragments licensed from Max Planck Society and University Medical Center Göttingen, plus an option to acquire PC111, an antibody for severe dermatological conditions 1. The company reported an operating loss of $7.5 million for 2025, and CDMO revenues do not yet cover costs 1.
Segments
CDMO (Scinai Biopharma Services)
The CDMO unit provides analytical development, process development and cGMP manufacturing of clinical-stage materials, with an emphasis on early-stage clients mainly from Israel and the United States 1. The Yavne acquisition adds small-molecule capabilities, and the Recipharm collaboration lets clients move to late-stage clinical and commercial manufacturing 1.
R&D therapeutics
The IL-17 NanoAb program is under strategic review, with intradermal and bispecific approaches under consideration for psoriasis 1. The PC111 program targets pemphigus, SJS and TEN, rare conditions with no approved therapies for SJS and TEN, and the option depends on FENG grant funding 1.
Market context
Trends
- Intensified IL-17 competitionheadwind
The large number of approved products and candidates for similar indications could make a new IL-17 monotherapy face commercial difficulties if it does not differentiate 1.
- EU FENG grantsmixed
Funding through the European FENG program could support development without dilution if applications are approved, with a decision expected in July 2026 1.
- CDMO consolidationmixed
The Recipharm Israel acquisition and the expansion into small molecules could broaden the CDMO offer and attract new clients, but integration involves costs and staff transfers 1.
- Limited fundingheadwind
Insufficient capital for the next 12 months could restrict research programs and force cost reductions 1.
Competitive position
In IL-17 therapies the company faces approved products and development candidates targeting the same indications, and in CDMO it competes with other providers of services for early-stage biotech companies 1. The source does not name specific competitors in these passages and gives no market value figures 1.
- Approved and developing IL-17 therapy makers
Approved products and development candidates for psoriasis and psoriatic arthritis are direct competitors of the IL-17 program 1.
- CDMO providers for early-stage biotech
Contract service companies offering development and cGMP manufacturing to small clients compete directly for the same customers 1.
- Other dermatology antibody developers
Pemphigus and SJS/TEN are treated with corticosteroids, immunosuppressants and biologics such as rituximab, which compete with PC111 1.
- Manufacturing partners with global networks
Recipharm, through its global network, can act both as a partner and a competitor for late-stage clinical and commercial manufacturing 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)20 Oct 2026
- Current report (foreign issuer)16 Oct 2026
- Current report (foreign issuer)15 Oct 2026
- Current report (foreign issuer)13 Oct 2026
- Current report (foreign issuer)21 Sept 2026
- Current report (foreign issuer)08 Sept 2026
- Current report (foreign issuer)26 Aug 2026
- Current report (foreign issuer)19 Aug 2026
- Current report (foreign issuer)17 Jun 2026
- Current report (foreign issuer)15 Jun 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / Scinai Immunotherapeutics Ltd. · 01 Apr 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.